Compare iShares Global Clean Energy ETF (ICLN) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Global Clean Energy ETF vs Natera Inc. Common Stock — how do they compare? iShares Global Clean Energy ETF trades at $16.43 (market cap $2.13B), while Natera Inc. Common Stock trades at $393.93 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 26.8× iShares Global Clean Energy ETF's market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, iShares Global Clean Energy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares Global Clean Energy ETF for 88 Days and Natera Inc. Common Stock for 0 Days on average.
| ICLN | NTRA | |
|---|---|---|
Market Cap | $2.13B | $57.03B |
Volume | 5,190,061 | 1,131,157 |
52-Week High | $23.75 | $425.64 |
52-Week Low | $16.00 | $179.42 |
Typical Hold Time | 88 Days | 0 Days |
Sector | — | Health |
Enterprise Value | — | $56.18B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICLN trades at $17.18 with a slight 0.35% daily gain, though technical indicators signal bearish momentum with 15 sell signals versus 1 buy. The ETF faces headwinds from higher expense ratios and volatility compared to traditional energy peers, with recent news highlighting underperformance against fossil fuel ETFs. Support and resistance cluster tightly around $17, indicating potential consolidation.
Outlook remains cautious due to weak technicals and competitive pressure from lower-cost energy ETFs. Long-term growth hinges on renewable energy adoption, but near-term risks include fee disadvantages and sector volatility. Investors should weigh clean energy exposure against more stable traditional energy alternatives.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About iShares Global Clean Energy ETF
The index is designed to track the performance of approximately 100 clean energy-related companies. The fund generally invests at least 80% of its assets in the component securities of the target index. The index may invest up to 20% of its assets in certain futures, trading options and swap contracts, cash and cash equivalents, as well as in securities not included in the index. It is non-diversified.
Read more on ICLN →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
